To undertake an overview on the overall effects of Tripterygium glycosides (TG) combined with Leflunomide (LEF) for rheumatoid arthritis (RA).
We searched electronic databases from database establishment time to December 1, 2019. The clinical trial data of TG combined with LEF (trial group) and control group in the treatment of RA were collected. The Cochrane system was used to evaluate the quality of the literature. RevMan 5.3 software was used to conduct a meta-analysis of the eligible studies.
A total of 12 randomized controlled trials (RCTs) involving 834 patients with RA were included in this study. The meta-analysis results showed that morning stiffness (mean difference (MD) = -0.29, 95% confidential interval (CI) (-0.45, -0.12), =0.0005), tender joint count (MD = -1.51, 95% CI (-2.20, -0.83), =0.0001), swollen joint count (MD = -1.24, 95% CI (-1.59, -0.88), =0.0001), erythrocyte sedimentation rate (MD = -7.26, 95% CI (-9.92, -4.61), =0.0001), C-reactive protein (MD = -4.04, 95% CI (-4.93, -3.14), =0.0001), and rheumatoid factor (MD = -50.88, 95% CI (-72.30, -29.45), = 0.0001) in the trial groups were lower than those in the control groups. The total effective rate in the trial group was better than that in the control group (risk ratio (RR) = 1.20, 95% CI (1.13, 1.28), =0.00001). However, there was no significant difference of adverse events (RR = 0.83, 95% CI (0.61, 1.13), =0.23) while comparing the trial groups with the control groups.
Our results were found to be superior but limited evidence on the effectiveness of TG combined with LEF in the treatment of RA is available.
Copyright © 2020 Yi-Jing Yang et al.